Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer
The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.
EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer
EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer
EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer
Now Viewing
EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer
EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer
EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)
EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer
EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer
EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022
EP: 10.HER2+ mBC: First-Line Treatment Regimens
EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates
EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC
EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC
EP: 14.Emerging Data and Investigational Agents in HER2+ mBC
EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment
Related Videos
Related Content
